AU2014274586B2 - Nucleic acids and proteins from streptococcus groups A & B - Google Patents
Nucleic acids and proteins from streptococcus groups A & B Download PDFInfo
- Publication number
- AU2014274586B2 AU2014274586B2 AU2014274586A AU2014274586A AU2014274586B2 AU 2014274586 B2 AU2014274586 B2 AU 2014274586B2 AU 2014274586 A AU2014274586 A AU 2014274586A AU 2014274586 A AU2014274586 A AU 2014274586A AU 2014274586 B2 AU2014274586 B2 AU 2014274586B2
- Authority
- AU
- Australia
- Prior art keywords
- protein
- seq
- nucleic acid
- vector
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 34
- 241000194017 Streptococcus Species 0.000 title claims abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title claims 23
- 108020004707 nucleic acids Proteins 0.000 title claims 14
- 102000039446 nucleic acids Human genes 0.000 title claims 14
- 108091005461 Nucleic proteins Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 8
- 241000193996 Streptococcus pyogenes Species 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 239000013598 vector Substances 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 241000175212 Herpesvirales Species 0.000 claims 1
- 241000713333 Mouse mammary tumor virus Species 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000006179 pH buffering agent Substances 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 abstract 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 abstract 1
- 230000037006 agalactosis Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides proteins from group B streptococcus (Streptococcus agalactia) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
Description
2014274586 19 Dec 2014
EDITORIAL NOTE 2014274586
There are 3024 pages of description.
The accepted description can be found as physical media in the basement.
Claims (25)
- The claims defining the invention are as follows:1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of: (a) nucleic acid encoding a protein comprising SEQ ID NO: 4212, but not comprising SEQ ID NO: 4211; (b) a mutant sequence having 50% or greater sequence identity to SEQ ID NO: 4211; or (c) a sequence encoding a fusion protein comprising a protein which has 50% or greater sequence identity to SEQ ID NO: 4212.
- 2. The nucleic acid molecule of claim 1, wherein the nucleic acid sequence having 50% or greater sequence identity to SEQ ID NO: 4211, but not comprising SEQ ID NO: 4211, encodes a functional mutant or homolog of SEQ ID NO: 4212.
- 3. A vector comprising a nucleic acid sequence selected from the group consisting of (i) the nucleic acid sequence of claim 1 or 2, (ii) a nucleic acid sequence comprising SEQ ID NO: 4211, (iii) a nucleic acid sequence encoding a protein comprising a fragment of 100 or more consecutive nucleotides of SEQ ID NO: 4212; or (iv) a nucleic acid sequence encoding a fusion protein comprising a sequence which has at least 90% sequence identity to SEQ ID NO: 4212.
- 4. The vector of claim 3, further comprising a promoter.
- 5. The vector of claim 4, wherein the promoter is operably linked to the nucleic acid sequence of any one of claims 1 to 3.
- 6. The vector of claim 4 or 5, wherein the promoter is a mammalian promoter.
- 7. The vector of any one of claims 4 to 6, wherein the promoter is selected from the group consisting of the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and a sequence derived from a non-viral gene.
- 8. The vector of any one of claims 4 to 7, wherein the promoter is inducible.
- 9. The vector of any one of claims 4 to 7, wherein the promoter is constitutive.
- 10. The vector of any one of claims 3 to 9, wherein the vector is selected from the group consisting of a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes viral vector, and an alphavirus vector.
- 11. An isolated protein selected from the group consisting of: (a) a protein comprising the amino acid sequence SEQ ID NO: 4212; (b) a protein having 50% or greater sequence identity to (a); (c) a protein comprising the amino acid sequence of SEQ ED NO: 4212, produced by recombinant expression in a cell other than a Streptococcus pyogenes cell; (d) a functional mutant or homolog of SEQ ID NO: 4212, with at least 90% sequence identity to SEQ ID NO: 4212; (e) a protein comprising a fragment of 7 or more, such as 100 or more, consecutive amino acids of SEQ ID NO: 4212; (f) a hybrid protein represented by the formula NH2-A-[-X-L-]„-B-COOH, wherein X is the amino acid sequence SEQ ED NO:4212, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer, wherein n is greater than 1; (g) a fusion protein comprising a polypeptide comprising a sequence which has at least 90% sequence identity to SEQ ID NO: 4212; and (h) an antibody that binds a protein comprising SEQ ID NO: 4212.
- 12. The protein of claim 11, wherein the protein is an antibody and wherein the antibody is monoclonal, chimeric, humanized or fully human.
- 13. The protein of claim 12, further comprising a detectible label.
- 14. The protein of claim 11, wherein the protein is a fusion protein comprising a polypeptide comprising a sequence which has at least 90% sequence identity to SEQ ID NO: 4212, and wherein the fusion protein comprises a histidine tag, a glutathione S-transferase (GST) tag, a signal sequence, or a leader sequence.
- 15. A cell comprising the nucleic acid of any of claims 1 to 2 or a nucleic acid comprising SEQ ID NO: 4211, the vector of any of claims 3 to 10 or the protein of any of claims 11 to 14.
- 16. The cell of claim 15, wherein the cell is a mammalian cell.
- 17. A composition comprising the nucleic acid of any of claims 1 to 2 or a nucleic acid comprising SEQ ID NO: 4211, the vector of claims 3 to 10, or the protein of any of claims 11 to 14, a pH buffering substance, and a pharmaceutically acceptable vehicle.
- 18. The composition of claim 17, wherein the composition comprises two or more proteins of claim 11, each protein selected from the group consisting of: (a) a protein comprising the amino acid sequence SEQ ID NO: 4212; (b) a protein having 50% or greater sequence identity to (a); and (c) a protein comprising a fragment of 7 or more consecutive amino acids from the amino acid sequence SEQ ID NO: 4212.
- 19. An in vitro method of inducing the expression of the protein of claim 11 in a mammalian cell, said method comprising introducing into the cell a nucleic acid encoding said protein.
- 20. The method of claim 19, wherein the nucleic acid encodes SEQ ED NO: 4212 and a protein comprising SEQ ED NO: 4212 is expressed.
- 21. The nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18, for use as a medicament.
- 22. The nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18, for use as a vaccine.
- 23. The nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18, for use in the manufacture of a medicament for treating or preventing a disease and/or infection caused by streptococcus.
- 24. A method of treating or preventing a disease and/or infection caused by streptococcus in a patient comprising administering to the patient the nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18.
- 25. A vector comprising a nucleic acid sequence encoding the isolated protein of claim 11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014274586A AU2014274586B2 (en) | 2000-10-27 | 2014-12-19 | Nucleic acids and proteins from streptococcus groups A & B |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0026333.5 | 2000-10-27 | ||
| GB0028727.6 | 2000-11-24 | ||
| GB0105640.7 | 2001-03-07 | ||
| AU2012200299A AU2012200299B2 (en) | 2000-10-27 | 2012-01-18 | Nucleic acids and proteins from streptococcus groups A and B |
| AU2014274586A AU2014274586B2 (en) | 2000-10-27 | 2014-12-19 | Nucleic acids and proteins from streptococcus groups A & B |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012200299A Division AU2012200299B2 (en) | 2000-10-27 | 2012-01-18 | Nucleic acids and proteins from streptococcus groups A and B |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017201090A Division AU2017201090B2 (en) | 2000-10-27 | 2017-02-23 | Nucleic acids and proteins from streptococcus groups A & B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014274586A1 AU2014274586A1 (en) | 2015-01-22 |
| AU2014274586B2 true AU2014274586B2 (en) | 2017-01-05 |
Family
ID=45812134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012200299A Ceased AU2012200299B2 (en) | 2000-10-27 | 2012-01-18 | Nucleic acids and proteins from streptococcus groups A and B |
| AU2014274586A Expired AU2014274586B2 (en) | 2000-10-27 | 2014-12-19 | Nucleic acids and proteins from streptococcus groups A & B |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012200299A Ceased AU2012200299B2 (en) | 2000-10-27 | 2012-01-18 | Nucleic acids and proteins from streptococcus groups A and B |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU2012200299B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028891A2 (en) * | 2000-10-04 | 2002-04-11 | Institut Pasteur | Listeria inocua, genome and applications |
-
2012
- 2012-01-18 AU AU2012200299A patent/AU2012200299B2/en not_active Ceased
-
2014
- 2014-12-19 AU AU2014274586A patent/AU2014274586B2/en not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028891A2 (en) * | 2000-10-04 | 2002-04-11 | Institut Pasteur | Listeria inocua, genome and applications |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014274586A1 (en) | 2015-01-22 |
| AU2012200299A1 (en) | 2012-02-09 |
| AU2012200299B2 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102482994B1 (en) | Vaccine composition for preventing or treating infection of SARS-CoV-2 | |
| AU712907B2 (en) | Method for treatment of cancer and infectious diseases and compositions useful in same | |
| Raben et al. | A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. | |
| JP2865300B2 (en) | Human B cell stimulating factor 2 receptor protein | |
| CN102741405B (en) | System for increasing gene expression, and vector supporting said system | |
| JP3328644B2 (en) | Isolation and recultivation of pathogenic Borrelia burgdorferi strain, pathogenic Borrelia burgdorferi | |
| EP0584167B1 (en) | Recombinant dna coding for signal peptide, selective interacting polypeptide and membrane anchoring sequence | |
| JPH03201979A (en) | Highly stable recombinant gamma-interferon | |
| CA2225378A1 (en) | Cytokine that induces apoptosis | |
| CA2281952A1 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| CN113061168B (en) | Truncated fever with thrombocytopenia syndrome virus Gn protein and application thereof | |
| CA2209360A1 (en) | Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen | |
| US20040002469A1 (en) | Method for treatment of cancer and infectious diseases and compositions useful in same | |
| CN103080309A (en) | Partial region polypeptide of REIC/DKK-3 protein | |
| EP0432510A1 (en) | Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells | |
| EP2910634B1 (en) | Vaccine for preventing porcine edema disease | |
| US7247712B2 (en) | Complex of hepatitis B virus-specific antigenic peptides associated with heat shock proteins and the application thereof | |
| KR20070114263A (en) | Method for producing protective antigen derived from Bacillus anthracis | |
| WO2024222926A1 (en) | Fusion protein capable of being self-assembled into nanoparticles, and use thereof in immunization | |
| CA2195090A1 (en) | Lkp pilin structural genes and operon of nontypable haemophilus influenzae | |
| JPH10508479A (en) | Production of recombinant peptides as natural hydrophobic peptide analogs | |
| AU2014274586B2 (en) | Nucleic acids and proteins from streptococcus groups A & B | |
| US8318662B2 (en) | Protein increasing cell infectivity of herpes simplex virus and use thereof | |
| US20210189010A1 (en) | Development of recombinant chicken igy scfv antibody raised against human tymidine kinase 1 expressed in prokaryotic cells and use thereof | |
| AU2005203173B2 (en) | Super-antigen fusion proteins and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMFD | Amendment of filing date |
Effective date: 20141219 |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: J. CRAIG VENTER INSTITUTE, INC.; NOVARTIS AG Free format text: FORMER APPLICANT(S): J. CRAIG VENTER INSTITUTE, INC.; NOVARTIS VACCINES AND DIAGNOSTICS, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |